Introduction
============

Rheumatoid arthritis (RA) is a symmetric polyarticular arthritis that primarily affects the small diarthrodial joints of the hands and feet, while juvenile idiopathic arthritis (JIA) is caused by unknown etiology and persists at least 6 weeks in children under the age of 16, which does not contain other known conditions ([@ref-12]; [@ref-42]). The prevalence rate of RA varies from 0.41 to 0.54% from 2004 to 2014 based on US administrative health insurance claims databases ([@ref-21]), which is observably greater than the prevalence rate of JIA ranging from 0.0038 to 0.40% according to a systematic literature review including 29 articles ([@ref-54]).

Phenotypically, RA and JIA are similar in some aspects. They show some common symptoms and physical signs such as joint pain and swelling, limited joint mobility and deformity, morning stiffness, elevated rheumatoid factor, fever, etc. Some of the subtypes of JIA, such as polyarticular JIA, are particularly similar to RA. However, with distinct clinical and pathological features of these two diseases being noted, they have been defined as separate diseases by International League of Associations for Rheumatology ([@ref-39]). In particular, JIA is heterogeneous with variable clinical presentation and outcome. It has been classified into seven subtypes, including oligoarticular JIA (persistent/ extended), polyarticular JIA with negative rheumatoid factor (RF), polyarticular JIA with positive RF, psoriatic JIA, enthesitis related arthritis, systemic JIA and undifferentiated JIA ([@ref-33]). RA is more homogeneous but with a poorer outcome.

It has long been recognized that both RA and JIA are related to autoimmune and inflammatory disorders ([@ref-44]; [@ref-47]). Population-based heritability estimates for RA and JIA are both 60% approximately ([@ref-31]; [@ref-41]). Single-nucleotide polymorphism (SNP)-based heritability for RA has been reported to be around 50% ([@ref-49]; [@ref-50]), slightly lower than that of JIA estimated to be 73% ([@ref-26]). Certain alleles in the HLA region are strong genetic predisposition factors for RA and JIA. It has been reported that for both RA and JIA, the odds ratio of HLA region is about 2.8, while that of most non-HLA loci is only 1.1 to 1.4. ([@ref-33]; [@ref-17]; [@ref-56]) The genetic predisposition of JIA is attributable to HLA class II molecules (HLA-DRB1, HLA-DPB1), HLA class I molecules and non-HLA genes. The clinical presentation of RF-positive JIA resembles that of RA, and they share the HLA-DRB1 epitope ([@ref-8]; [@ref-20]). The HLA-DRB1\*04 confers a protective role in JIA before the age of 6, while it renders an increased risk of RA ([@ref-33]). The immunopathogenesis of RA has become clear in recent years, but the pathogenesis of JIA remains unknown ([@ref-13]; [@ref-32]).

With the rapid development of genomic technology, a large number of genetic variants associated with RA or JIA have been identified. To date, genome-wide association studies (GWASs) have identified a large number of variants associated with RA and JIA respectively. A total of 789 RA-associated variants from 52 studies and 129 JIA-associated variants from 11 studies have been reported in GWAS Catalog (association testing *P*-value \<1 × 10^−5^) ([@ref-6]), including 101 loci associated with RA and around 30 loci associated with JIA at genome-wide significant level. We aimed to compare the genetic architecture of RA and JIA at multiple levels systematically.

In this study, we conducted gene, pathway and network analyses of RA and JIA using robust and computational efficient methods based on their summary GWAS statistics. We compared genetic difference and similarity between RA and JIA, identified their shared genetic signature. Significant overlap in genes and pathways were observed between these two diseases.

Materials and Methods
=====================

Data collection
---------------

RA genetic loci information came from GWAS summary statistics of a trans-ethnic study ([@ref-35]) including a total of 29,880 RA cases and 73,758 controls of European and Asian ancestries. Summary statistics was downloaded from GWAS catalog (<https://www.ebi.ac.uk/gwas/>) ([@ref-6]). All RA patients met the RA diagnostic criteria established by the American College of Rheumatology in 1987 ([@ref-3]), or were confirmed by a professional rheumatologist ([@ref-35]).

JIA genetic loci information came from two resources. First, summary statistics of our previous GWAS on JIA ([@ref-11]) was included in the current study. Our JIA GWAS is composed of discovery and replication cohorts with 1166 JIA cases and 9500 unrelated controls of European ancestry totally. Summary statistics of meta-analysis on the discovery and replication cohorts were used in our current study. Second, JIA variants revealed in published GWASs ([@ref-5]; [@ref-7]; [@ref-11]; [@ref-18]; [@ref-19]; [@ref-25]; [@ref-37]; [@ref-55]) were extracted from GWAS catalog ([@ref-6]).

Gene-based association analysis
-------------------------------

A gene-based association analysis for RA and JIA was performed using *fastBAT* method ([@ref-4]) implemented in GCTA v1.91.7 ([@ref-58]) respectively, based on GWAS summary statistics of RA or JIA and linkage disequilibrium (LD) information from EUR population in the 1000 Genomes Project ([@ref-53]). Each gene region was defined as its transcript region and 50kb upstream/downstream, and the threshold for LD pruning was set to r^2^-value \>0.9, following the default setting of *fastBAT*. The gene list of human genome used by *fastBAT* method contains 24765 annotated genes ([@ref-4]), thus the genome-wide significant threshold for gene based tests was set at 0.05/24765 = 2 × 10^−6^. JIA SNPs in GWAS catalog was also mapped to genes according to its report ([@ref-6]).

Protein-protein interaction network and pathway enrichment analyses
-------------------------------------------------------------------

Competitive pathway enrichment analysis and protein-protein interaction (PPI) network visualization analysis were both performed using GWAS summary-level data by GSA-SNP2 (<https://sites.google.com/view/gsasnp2>) ([@ref-59]). The LD information in the European population from the 1000 Genomes Project ([@ref-53]) was used to reduce false positives by combining highly correlated adjoining genes. Each gene region was defined as its transcript region and 20 kb upstream/downstream, as the default setting of GSA-SNP2. Gene-set database used for pathway construction were *C2(curated gene sets)CP(canonical pathways)v5.2*, which is a collection of online pathway databases such as BioCarta (<http://software.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=CP:BIOCARTA>) ([@ref-34]), KEGG (<https://www.genome.jp/kegg/>) ([@ref-22]; [@ref-23]; [@ref-24]), Reactome (<https://reactome.org/>) ([@ref-10]) and PID ([@ref-46]) by Molecular Signatures Database (MSigDB) (<http://software.broadinstitute.org/gsea/msigdb>) ([@ref-27]; [@ref-28]; [@ref-51]). The network data resource was the STRING database (<https://string-db.org/>) ([@ref-52]). Multiple-testing adjustment was performed and Q-value \< 0.05 was set as the significance threshold. Global visual networks were constructed at a threshold of gene-score \< 0.005 and Q-value \< 0.05.

Results
=======

SNP-level comparison
--------------------

A total of 26,285 SNPs ([Table S1](#supp-1){ref-type="supplementary-material"}) in RA study and 105 SNPs ([Tables S2](#supp-2){ref-type="supplementary-material"}, [S3](#supp-3){ref-type="supplementary-material"}) in JIA study reached genome-wide significance threshold *P*-value \<5 × 10^−8^, and these two diseases shared 47 significant SNPs. Among these SNPs, 37 were located in the human leukocyte antigen (HLA) region on chromosome 6. The rest 10 SNPs were located in or close to 9 genes ([Table 1](#table-1){ref-type="table"}). Interestingly, 8 SNPs located in the HLA region showed opposite direction of effects, which meant risk allele of JIA could be protective allele for RA and vice versa.

Gene-based comparison
---------------------

To increase statistical power and to consider the combined effects of SNPs in genes, we conducted gene-disease association analyses, based on SNP-level summary statistics and taking into account of LD between SNPs. Several methods have been developed for computing gene-level associations based on SNP-level summary statistics, such as the commonly used PLINK ([@ref-43]) set-baesd test and software VEGAS (Versatile Gene-based Association Study) ([@ref-30]), which are permutation and simulation-based approaches respectively. Both methods rely on resampling which is computationally intensive. Here, we adopted the *fastBAT* method which was a robust set-based association test computing the *P*-value of a gene with a number of SNPs from an approximated distribution ([@ref-4]). 431 genes located at 50 loci reached genome-wide significance in the RA dataset, including 17 known loci ([@ref-1]; [@ref-6]; [@ref-9]; [@ref-40]; [@ref-45]; [@ref-61]) and 33 novel loci which should be examined in future replication studies ([Table S4](#supp-4){ref-type="supplementary-material"}).

10.7717/peerj.8234/table-1

###### Genome-wide significant SNPs shared by RA and JIA (*P*-value \< 5 × 10^−8^).

The raw data of genome-wide significant SNPs of RA are presented in [Table S1](#supp-1){ref-type="supplementary-material"}; and the raw data of genome-wide significant SNPs of JIA are shown in [Tables S2](#supp-2){ref-type="supplementary-material"} and [S3](#supp-3){ref-type="supplementary-material"}.
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                                                                                    **RA**   **JIA**                                                            
  ---------------------------------------------------------------- ---- ----------- -------- --------- ---------- --- ------ ---------- ----------------------- -----------------------
  [rs6679677](http://www.ncbi.nlm.nih.gov/snp/?term=rs6679677)     1    114303808   A        1.81      2.1E−149   A   1.59   3E−25      644bp 3′ of *RSBN1*     
  [rs10174238](http://www.ncbi.nlm.nih.gov/snp/?term=rs10174238)   2    191973034   G        1.14      1.2E−13    G   1.29   1E−13      *STAT4*                 
  [rs10213692](http://www.ncbi.nlm.nih.gov/snp/?term=rs10213692)   5    55442249    T        1.19      1.3E−17               1.27       3E−11                   *ANKRD55*
  [rs7731626](http://www.ncbi.nlm.nih.gov/snp/?term=rs7731626)     5    55444683    G        1.20      7.3E−24    A          1E−10      *ANKRD55*               
  [rs2517930](http://www.ncbi.nlm.nih.gov/snp/?term=rs2517930)     6    29745075    T        1.18      1.7E−31    T   1.47   8.95E−11   14kb 3′ of *HCG4*       
  [rs2975033](http://www.ncbi.nlm.nih.gov/snp/?term=rs2975033)     6    29822261    A        1.18      1.6E−33    A   1.47   6.48E−10   23kb 3′ of *HLA-G*      
  [rs12206499](http://www.ncbi.nlm.nih.gov/snp/?term=rs12206499)   6    29937127    G        1.16      6.4E−26    G   1.41   3.59E−08   5.8kb 5′ of *HCG9*      
  [rs3823355](http://www.ncbi.nlm.nih.gov/snp/?term=rs3823355)     6    29942083    T        1.16      6.5E−26    T   1.43   1.10E−08   807bp 5′ of *HCG9*      
  [rs6904029](http://www.ncbi.nlm.nih.gov/snp/?term=rs6904029)     6    29943067    A        1.16      6.8E−26    A   1.43   1.44E−08   *HCG9*                  
  [rs3823375](http://www.ncbi.nlm.nih.gov/snp/?term=rs3823375)     6    29944158    C        1.16      1.7E−25    C   1.44   3.10E−09   *HCG9*                  
  [rs9366752](http://www.ncbi.nlm.nih.gov/snp/?term=rs9366752)     6    30024677    T        1.09      1.6E−09    T   1.51   2.97E−10   *ZNRD1-AS1*             
  [rs1265048](http://www.ncbi.nlm.nih.gov/snp/?term=rs1265048)     6    31081409    C        1.12      5.3E−17    C   1.44   2.91E−09   1.1kb 5′ of *C6orf15*   
  [rs13202464](http://www.ncbi.nlm.nih.gov/snp/?term=rs13202464)   6    31344583    G        1.19      1.5E−15    G   2.00   2.09E−11   20kb 5′ of *HLA-B*      
  [rs9266689](http://www.ncbi.nlm.nih.gov/snp/?term=rs9266689)     6    31348580    G        1.14      3.3E−19    G   1.54   6.16E−11   19kb 5′ of *MICA*       
  [rs2844533](http://www.ncbi.nlm.nih.gov/snp/?term=rs2844533)     6    31350802    A        1.30      6.6E−55    A   1.61   2.90E−08   17kb 5′ of *MICA*       
  [rs2261033](http://www.ncbi.nlm.nih.gov/snp/?term=rs2261033)     6    31603591    G        1.56      4.2E−183   G   1.48   5.09E−09   *PRRC2A*                
  [rs6941112](http://www.ncbi.nlm.nih.gov/snp/?term=rs6941112)     6    31946614    A        1.31      6.1E−83    A   1.42   3.20E−09   *STK19*                 
  [rs8111](http://www.ncbi.nlm.nih.gov/snp/?term=rs8111)           6    32083175    T        1.33      7.2E−86    T   1.49   5.60E−11   *ATF6B*                 
  [rs204999](http://www.ncbi.nlm.nih.gov/snp/?term=rs204999)       6    32109979    A        1.55      5.5E−134   A   1.53   5.88E−09   6.2kb 3′ of *PRRT1*     
  [rs17576984](http://www.ncbi.nlm.nih.gov/snp/?term=rs17576984)   6    32212985    C        1.54      3.0E−72    T   1.86   1.66E−12   21kb 5′ of *NOTCH4*     
  [rs570963](http://www.ncbi.nlm.nih.gov/snp/?term=rs570963)       6    32289594    A        1.18      2.9E−18    G   1.70   8.91E−11   *C6orf10*               
  [rs910049](http://www.ncbi.nlm.nih.gov/snp/?term=rs910049)       6    32315727    C        1.19      5.2E−24    C   1.65   5.48E−10   *C6orf10*               
  [rs2395148](http://www.ncbi.nlm.nih.gov/snp/?term=rs2395148)     6    32321554    G        1.41      1.0E−20    T   3.62   1.08E−25   *C6orf10*               
  [rs6907322](http://www.ncbi.nlm.nih.gov/snp/?term=rs6907322)     6    32324945    G        1.14      1.7E−15    A   1.69   9.99E−15   *C6orf10*               
  [rs9268365](http://www.ncbi.nlm.nih.gov/snp/?term=rs9268365)     6    32333439    G        1.16      1.3E−20    T   1.66   4.98E−14   *C6orf10*               
  [rs3129941](http://www.ncbi.nlm.nih.gov/snp/?term=rs3129941)     6    32337686    G        1.64      1.4E−133   G   1.60   1.48E−09   *C6orf10*               
  [rs41291794](http://www.ncbi.nlm.nih.gov/snp/?term=rs41291794)   6    32425762    A        1.65      1.1E−63               2.10       4E−15                   13kb 3′ of *HLA-DRA*
  [rs2395185](http://www.ncbi.nlm.nih.gov/snp/?term=rs2395185)     6    32433167    T        2.01      1.0E−250   G   1.81   1.19E−16   20kb 3′ of *HLA-DRA*    
  [rs477515](http://www.ncbi.nlm.nih.gov/snp/?term=rs477515)       6    32569691    A        1.99      1.0E−250   G   1.89   3.19E−18   12kb 5′ of *HLA-DRB1*   
  [rs2516049](http://www.ncbi.nlm.nih.gov/snp/?term=rs2516049)     6    32570400    C        2.00      1.0E−250   T   1.89   2.62E−18   13kb 5′ of *HLA-DRB1*   
  [rs2858870](http://www.ncbi.nlm.nih.gov/snp/?term=rs2858870)     6    32572251    T        1.86      1.1E−77    T   2.19   8.41E−12   15kb 5′ of *HLA-DRB1*   
  [rs7775055](http://www.ncbi.nlm.nih.gov/snp/?term=rs7775055)     6    32657916    C        1.56      1.4E−60    C   6.01   3E−174     23kb 5′ of *HLA-DQB1*   
  [rs9275224](http://www.ncbi.nlm.nih.gov/snp/?term=rs9275224)     6    32659878    G        2.13      1.0E−250   G   1.41   1.06E−08   25kb 5′ of *HLA-DQB1*   
  [rs6457617](http://www.ncbi.nlm.nih.gov/snp/?term=rs6457617)     6    32663851    T        2.14      1.0E−250   T   1.40   1.10E−08   29kb 5′ of *HLA-DQB1*   
  [rs2858308](http://www.ncbi.nlm.nih.gov/snp/?term=rs2858308)     6    32670000    G        1.61      7.8E−92    G   1.98   1.94E−08   36kb 5′ of *HLA-DQB1*   
  [rs2856705](http://www.ncbi.nlm.nih.gov/snp/?term=rs2856705)     6    32670956    C        1.61      1.0E−91    C   1.99   1.64E−08   36kb 5′ of *HLA-DQB1*   
  [rs13192471](http://www.ncbi.nlm.nih.gov/snp/?term=rs13192471)   6    32671103    C        1.49      4.8E−123   C   1.93   1.93E−19   37kb 5′ of *HLA-DQB1*   
  [rs1794275](http://www.ncbi.nlm.nih.gov/snp/?term=rs1794275)     6    32671248    A        1.33      3.7E−69    A   1.82   3.47E−13   37kb 5′ of *HLA-DQB1*   
  [rs7765379](http://www.ncbi.nlm.nih.gov/snp/?term=rs7765379)     6    32680928    G        1.89      1.0E−250   G   1.68   3.11E−10   28kb 5′ of *HLA-DQA2*   
  [rs4713610](http://www.ncbi.nlm.nih.gov/snp/?term=rs4713610)     6    33107955    G        1.27      5.7E−49    G   1.54   7.54E−09   11kb 3′ of *HLA-DPB2*   
  [rs9277912](http://www.ncbi.nlm.nih.gov/snp/?term=rs9277912)     6    33124658    T        1.26      1.1E−48    T   1.51   2.61E−08   5.8kb 3′ of *COL11A2*   
  [rs706778](http://www.ncbi.nlm.nih.gov/snp/?term=rs706778)       10   6098949     T        1.09      1.5E−10    T          6E−09      *IL2RA*                 
  [rs9532434](http://www.ncbi.nlm.nih.gov/snp/?term=rs9532434)     13   40355913    C        1.10      1.0E−11               1.19       5E−08                   *COG6*
  [rs3825568](http://www.ncbi.nlm.nih.gov/snp/?term=rs3825568)     14   69260588    T        1.08      2.7E−08               1.30       1E−08                   802bp 5′ of *ZFP36L1*
  [rs2847293](http://www.ncbi.nlm.nih.gov/snp/?term=rs2847293)     18   12782448    A        1.12      1.2E−10    A   1.31   1E−12      3kb 3′ of *PTPN2*       
  [rs34536443](http://www.ncbi.nlm.nih.gov/snp/?term=rs34536443)   19   10463118    G        1.46      4.4E−16               1.79       1E−10                   *TYK2*
  [rs8129030](http://www.ncbi.nlm.nih.gov/snp/?term=rs8129030)     21   36712588    A        1.09      2.5E−09               1.28       5E−09                   291kb 5′ of *RUNX1*

**Notes.**

SNPsingle nucleotide polymorphismChrchromosomePosposition on human genome build hg19 (NCBI GRCh37)RArheumatoid arthritisJIAjuvenile idiopathic arthritisAllelerisk alleleORodds ratio of risk allelePvaldisease association P-value of risk SNPRefSeq genethe closest gene to each SNP and their relative positions based on Reference sequence (RefSeq) database ([@ref-36])

However only genes in the HLA region showed genome-wide significant association with JIA, which was likely due to the limited power of our previous GWAS ([Table S5](#supp-5){ref-type="supplementary-material"}). A total of 75 significant genes or regions in the HLA were shared by JIA and RA ([Table S6](#supp-6){ref-type="supplementary-material"}). Then we checked whether significant genes in RA contained additional genome-wide significant SNPs in JIA reported in GWAS catalog. Not surprisingly, one RA significant gene in the HLA region and 8 genes outside the HLA region containing genome-wide significant SNPs for JIA ([Table 2](#table-2){ref-type="table"}) were observed. Because the *fastBAT* method conducted LD-pruning before combining SNP statistics, the top SNP showed in [Table 2](#table-2){ref-type="table"} may not be the one with the best *P*-value in original GWAS.

10.7717/peerj.8234/table-2

###### Genome-wide significant genes outside the HLA region shared by RA and JIA (gene-based *P*-value \< 2 × 10^−6^).

The raw data of genome-wide significant genes of RA are shown in [Table S4](#supp-4){ref-type="supplementary-material"} and those of JIA are shown in [Tables S3](#supp-3){ref-type="supplementary-material"} and [S5](#supp-5){ref-type="supplementary-material"}.
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                                                                   **RA**                                                                   
  ---------------- ---- --------------------- ---------- --------- ---------------------------------------------------------------- ------- ----------------------------------------------------------------
  *PHTF1*          1    114239823-114301777   7.41E−43   1.7E−38   [rs1217416](http://www.ncbi.nlm.nih.gov/snp/?term=rs1217416)     3E−25   [rs6679677](http://www.ncbi.nlm.nih.gov/snp/?term=rs6679677)
  *RSBN1*          1    114304453-114355070   2.08E−19   2.8E−35   [rs3811019](http://www.ncbi.nlm.nih.gov/snp/?term=rs3811019)     3E−25   [rs6679677](http://www.ncbi.nlm.nih.gov/snp/?term=rs6679677)
  *ANKRD55*        5    55395506-55529186     2.42E−09   7.3E−24   [rs7731626](http://www.ncbi.nlm.nih.gov/snp/?term=rs7731626)     3E−11   [rs10213692](http://www.ncbi.nlm.nih.gov/snp/?term=rs10213692)
  *IL2RA*          10   6052656-6104333       4.58E−07   1.5E−10   [rs706778](http://www.ncbi.nlm.nih.gov/snp/?term=rs706778)       8E−10   [rs7909519](http://www.ncbi.nlm.nih.gov/snp/?term=rs7909519)
  *SUOX*           12   56391042-56399309     6.95E−07   3.7E−07   [rs701006](http://www.ncbi.nlm.nih.gov/snp/?term=rs701006)       4E−09   [rs1689510](http://www.ncbi.nlm.nih.gov/snp/?term=rs1689510)
  *LOC100996324*   18   12739484-12749421     5.76E−11   3.4E−15   [rs2847297](http://www.ncbi.nlm.nih.gov/snp/?term=rs2847297)     1E−12   [rs2847293](http://www.ncbi.nlm.nih.gov/snp/?term=rs2847293)
  *PTPN2*          18   12785476-12884334     9.99E−14   1.1E−15   [rs7241016](http://www.ncbi.nlm.nih.gov/snp/?term=rs7241016)     1E−12   [rs2847293](http://www.ncbi.nlm.nih.gov/snp/?term=rs2847293)
  *TYK2*           19   10461203-10491248     4.02E−07   2.7E−06   [rs12459219](http://www.ncbi.nlm.nih.gov/snp/?term=rs12459219)   1E−10   [rs34536443](http://www.ncbi.nlm.nih.gov/snp/?term=rs34536443)

**Notes.**

ChrchromosomeStart-Endstart and end boundaries of the gene region on human genome build UCSC hg19 (NCBI GRCh37)RArheumatoid arthritisJIAjuvenile idiopathic arthritisPvalgene-level P-value based on fastBAT methodTopSNPthe top associated GWAS SNPTopSNP_Pvalsmallest single-SNP GWAS P-value in the gene region

Pathway-level comparison
------------------------

GWAS pathway analysis consider either competitive null hypothesis or self-contained null hypothesis. Many methods for GWAS pathway analysis have been developed, but they are still subjected to the issues of low power and being influenced by some free parameters. The recently developed GSA-SNP2 package ([@ref-59]) uses the random set model to compute pathway enrichment with decent type I error control by integrating the gene scores adjusted by the number of SNPs mapped to each gene and removing high inter-gene correlated adjacent genes in each pathway. It does not require any key free parameters concurrently. We applied this method to our analyses. RA or JIA associated genes were enriched in numerous canonical pathways at a threshold of Q-value \<0.05. A total of 32 enriched pathways were shared by RA and JIA, which mostly were immune-related pathways, such as allograft rejection, type 1 diabetes mellitus, graft versus host disease, antigen processing and presentation, autoimmune thyroid disease, asthma, etc. ([Table S7](#supp-7){ref-type="supplementary-material"}). Most of these significant pathways were driven by genes in the HLA region. In order to explore the role of loci outside the HLA region for these two diseases, we performed pathway enrichment analysis again after removing loci in the HLA region based on their genomic coordinates. The HLA region was defined as chr6:28,477,797-33,448,354 (GRCh37/hg19). Pathways such as interleukin(IL)-27 pathway and NO2-dependent IL-12 pathway in natural killer (NK) cells were significantly enriched even after the HLA region loci were removed ([Table 3](#table-3){ref-type="table"}). Global networks were visualized at a threshold of gene-score \<0.005 ([Figs. 1](#fig-1){ref-type="fig"}&[2](#fig-2){ref-type="fig"}). We observed the common hub role of several genes such as *TYK2*. The networks before removing the HLA region were shown in [Figs. S1](#supp-8){ref-type="supplementary-material"} and [S2](#supp-9){ref-type="supplementary-material"}.

![The global network of RA after the HLA region being removed (Q-value \< 0.05, gene-score \< 0.005).\
The PPI network was constructed among proteins encoded by the significant RA-associated genes excluding those in the HLA region. The nodes in the figure represent the proteins and the connections between nodes indicate protein-protein interactions. The size of each node suggests the degrees of the connection between the node and the others.](peerj-08-8234-g001){#fig-1}

![The global network of JIA after the HLA region being removed (Q-value \< 0.05, gene-score \< 0.005).\
The PPI network was constructed among proteins encoded by the significant JIA-associated genes excluding those in the HLA region. The nodes in the figure represent the proteins and the connections between nodes indicate protein-protein interactions. The size of each node suggests the degrees of the connection between the node and the others.](peerj-08-8234-g002){#fig-2}
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###### Enriched pathways shared by RA and JIA after loci in the HLA region being removed (Q- value \< 0.05).

![](peerj-08-8234-g005)

                                             **RA**   **JIA**                               
  -------------------------- ---------- ---- -------- ---------- ---------- ---- ---------- ----------
  TYPE I DIABETES MELLITUS   KEGG       44   23       1.66E−07   1.58E−05   41   2.12E−05   0.001785
  IL27 PATHWAY               PID        26   26       0.001158   0.027447   25   4.79E−08   8.63E−06
  NO2IL12 PATHWAY            BIOCARTA   17   15       0.002316   0.047593   16   1.87E−05   0.001686

**Notes.**

Pathwayabbreviation for each enriched pathwayDatabasedatabase from which the pathways were extractedSizetotal number of genes in each pathwayRArheumatoid arthritisJIAjuvenile idiopathic arthritisCountthe number of RA/JIA- significant genes falling into each pathwayPvalP-value of each pathwayQvalQ-value of each pathway based on the trend curve adjusted gene scores

Discussion
==========

Despite the phenotypic similarity between JIA and RA, systematic comparison of genetic similarity and distinction between these two types of diseases are lacking. Large scale GWASs of RA and JIA respectively render us ability to conduct such comparison and to identify potential common mechanism in disease pathogenesis, which may help repositioning and designing treatment strategies.

To systematically compare the genetic architecture of the two diseases, we performed gene-level, pathway-level analyses and conducted comparison at each level. Not only did we observe a large amount of overlaps in the HLA region as expected, but we also observed several SNPs and genes which significantly associated with both diseases outside the HLA region. Among them, the risk alleles of several SNPs were different between the two diseases, which meant that a certain allele may play a risk role in one disease but a protective role in the other. These SNPs might be related to the differences in pathogenesis and phenotype between JIA and RA. As we did not perform genome-wide imputation analysis due to unavailability of individual-level data, the number of genome-wide significant SNPs shared by these two diseases was actually underestimated.

Due to the limited sample size of our JIA data, we could not perform analysis for each subtype of JIA with enough statistical power. However, the heterogeneity of JIA and the genetic basis of its subtypes are worth noting. Some HLA alleles show different directions of effects on different subtypes of JIA and RA. For instance, HLA-DRB1\*8, HLA-DRB1\*11 and HLA-DRB1\*13 are risk alleles of seronegative JIA, but do not exhibit association with seropositive polyarticular JIA and seronegative RA, and these HLA alleles render protective effect for seropositive RA. In particular, DRB1\*11 is also a risk allele of systemic JIA, while the other two alleles are not associated with this JIA subtype ([@ref-33]). As for alleles outside the HLA region, certain SNPs in genes *PTPN22* and *STAT1/STAT4* do not show association with systemic JIA, but confer risk for most other subtypes of JIA and RA ([@ref-33]). In a recent study, Hinks et al. demonstrated that RF-positive polyarticular JIA is more similar to adult RA compared to other JIA subtypes in terms of genetic profile examined on Immunochip ([@ref-20]; [@ref-38]). Further analysis of the genetic nature of different subtypes of JIA and RA would be helpful to optimize the classification of the two diseases, and may lead to more effective treatment and better prognosis.

We observed significant enrichment of *NO2-dependent IL12 pathway* and *IL27 pathway* for both RA and JIA. Macrophages release IL-12 which plays an important role in activation of NK cells and induces cytotoxicity with nitric oxide ([@ref-29]). NK cells are regarded as a bridge between innate and adaptive immunity, serving as a key regulator in the pathogenesis and development of autoimmune diseases ([@ref-14]). It has been reported that high percentages of NK cells and their activity were found in synovial fluid of active RA patients at advanced stage ([@ref-57]), and dysfunction of NK cells was also observed in patients with systemic-onset JIA and its complication ([@ref-15]). NO2-dependent IL12 pathway plays a unique role in the activation of NK cells by macrophage. The enrichment of this pathway in our analyses implies the potential role of abnormal IL-12-mediated activation of NK cell in the pathogenesis of RA and JIA. IL-12 has long been considered as a therapeutic target of arthritis and other autoimmune and inflammatory disorders ([@ref-16]; [@ref-48]). As a member of the IL-12 family, IL-27 induces T cell differentiation and causes immunosuppressive effects by inhibiting the development of Th17 cells ([@ref-60]). Previous studies have suggested that IL-27 is another key modulator of autoimmunity and elevation of IL-27 signaling may be inhibitory to some autoimmune diseases, such as multiple sclerosis or uveitis ([@ref-2]). Our results suggest that such therapeutic approach may be also applied to the management of RA and JIA.

Conclusion
==========

Our study identified genetic similarities and differences between RA and JIA at multiple levels. We observed a number of genes being associated with both diseases especially in the HLA region, and distinct genetic loci were found as well. Such systematic comparison and further functional characterization of these genetic loci and signaling pathways may lead to the identification of common drug targets for both diseases or drug repositioning, and may also contribute to the precision treatment of each disease.
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